Vor Biopharma Inc. (VOR) Balance Sheet
VOR balance sheet, 2025
December 31, 2025 · U.S. dollars$464.1M assets = $628.4M liabilities + −$164.3M equity
Liabilities exceed assets: shareholders’ equity is negative (−$164.3M).
Both columns are drawn to the same scale: what VOR owns equals what it owes plus shareholders’ equity. Hover a block for its value.
VOR financial health
Descriptive bands, not a rating. Fiscal 2025.
VOR balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $1.0M2018 | $464.1M2025 | +140.2%/yr | |
| Total liabilities | $7.8M2018 | $628.4M2025 | +87.3%/yr | |
| Shareholders’ equity | −$6.8M2018 | −$164.3M2025 | — | |
| Cash & short-term investments | $929,0002018 | $455.2M2025 | +142.3%/yr | |
| Total debt | $4.5M2018 | $3.0M2025 | −5.5%/yr | |
| Net cash (debt) | −$3.5M2018 | $452.2M2025 | +$455.7M | |
| Working capital | −$6.8M2018 | $432.9M2025 | +$439.8M | |
| Debt / equity | 0.382020 | 0.332024 | −0.05 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
VOR assets
VOR liabilities and equity
VOR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
VOR balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $455.2M | $91.9M | $137.2M | $230.2M | $207.5M | $48.5M | $6.5M | $929,000 |
| Cash & equivalents | $396.5M | $81.9M | $31.4M | $57.7M | $119.8M | $48.5M | $6.5M | $929,000 |
| Short-term investments | $58.7M | $10.0M | $105.8M | $172.5M | $87.7M | $0 | — | — |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $2.9M | $4.6M | $3.6M | $6.7M | $6.9M | $567,000 | $1.1M | $7,000 |
| Total current assets | $458.1M | $96.5M | $140.8M | $236.9M | $214.4M | $49.1M | $7.5M | $936,000 |
| Property, plant & equipment (net) | $3.5M | $41.6M | $50.1M | $57.1M | $22.5M | $21.8M | $728,000 | $71,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $2.6M | $4.8M | $18.9M | $5.3M | $5.7M | $5.0M | $1.6M | $0 |
| Total assets | $464.1M | $142.9M | $209.8M | $299.4M | $242.6M | $75.9M | $9.8M | $1.0M |
| Liabilities | ||||||||
| Accounts payable | $5.1M | $1.5M | $815,000 | $1.8M | $1.5M | $2.4M | $693,000 | $38,000 |
| Short-term debt | $280,000 | $4.2M | $3.8M | $3.3M | $1.8M | $863,000 | — | $4.5M |
| Deferred revenue | — | — | — | — | $6.3M | $6.3M | — | $1.4M |
| Total current liabilities | $25.2M | $18.6M | $15.6M | $13.1M | $10.2M | $10.2M | $2.2M | $7.8M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $3.0M | $31.8M | $35.7M | $38.9M | $18.0M | $18.3M | — | — |
| Other long-term liabilities | $603.3M | $27.6M | $43.5M | $35.6M | $16.2M | $17.4M | $693,000 | $2,000 |
| Total liabilities | $628.4M | $46.2M | $59.1M | $48.8M | $26.3M | $27.6M | $2.2M | $7.8M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $18,000 | $13,000 | $7,000 | $7,000 | $4,000 | $1,000 | — | — |
| Retained earnings (deficit) | −$1.15B | −$457.0M | −$340.1M | −$222.2M | −$130.1M | −$61.2M | −$17.9M | −$7.0M |
| Accumulated other comprehensive income | $41,000 | $22,000 | −$77,000 | −$770,000 | −$242.6M | — | $0 | −$30,000 |
| Total shareholders' equity | −$164.3M | $96.7M | $150.7M | $250.6M | $216.3M | $48.3M | $7.6M | −$6.8M |
| Key figures | ||||||||
| Total debt | $3.0M | $31.8M | $35.7M | $38.9M | $18.0M | $18.3M | — | $4.5M |
| Net cash (debt) | $452.2M | $60.1M | $101.5M | $191.3M | $189.5M | $30.2M | — | −$3.5M |
| Working capital | $432.9M | $77.9M | $125.2M | $223.8M | $204.2M | $38.9M | $5.4M | −$6.8M |
| Tangible book value | −$164.3M | $96.7M | $150.7M | $250.6M | $216.3M | $48.3M | $7.6M | −$6.8M |
| Current ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 | 4.81 | 3.45 | 0.12 |
| Quick ratio | 18.08 | 4.94 | 8.81 | 17.55 | 20.43 | 4.76 | 2.96 | 0.12 |
| Debt / equity | — | 0.33 | 0.24 | 0.16 | 0.08 | 0.38 | — | — |
| Equity / assets | −35.4% | 67.6% | 71.8% | 83.7% | 89.1% | 63.6% | 77.8% | −672.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $466.1M | $491.5M | $455.2M | $170.5M | $203.0M | $60.0M | $91.9M | $62.8M | $85.9M | $107.5M | $137.2M | $160.1M |
| Cash & equivalents | $107.9M | $169.9M | $396.5M | $160.5M | $193.0M | $50.0M | $81.9M | $52.8M | $76.1M | $45.0M | $31.4M | $45.0M |
| Short-term investments | $358.3M | $321.7M | $58.7M | $10.0M | $10.0M | $10.0M | $10.0M | $10.0M | $9.9M | $62.5M | $105.8M | $115.1M |
| Receivables | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $9.0M | $9.3M | $2.9M | $2.0M | $1.9M | $4.8M | $4.6M | $4.5M | $4.3M | $4.3M | $3.6M | $4.3M |
| Total current assets | $475.1M | $500.8M | $458.1M | $172.5M | $204.9M | $64.8M | $96.5M | $67.3M | $90.3M | $111.8M | $140.8M | $164.4M |
| Property, plant & equipment (net) | $3.4M | $3.4M | $3.5M | $3.3M | $24,000 | $39.7M | $41.6M | $43.8M | $45.9M | $48.0M | $50.1M | $52.1M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $2.6M | $2.6M | $2.6M | $437,000 | $420,000 | $4.8M | $4.8M | $4.9M | $5.5M | $7.2M | $18.9M | $6.5M |
| Total assets | $481.1M | $506.7M | $464.1M | $176.2M | $205.4M | $109.3M | $142.9M | $116.0M | $141.6M | $167.0M | $209.8M | $223.0M |
| Liabilities | ||||||||||||
| Accounts payable | $4.0M | $1.0M | $5.1M | $885,000 | $669,000 | $3.7M | $1.5M | $1.3M | $2.0M | $2.3M | $815,000 | $1.3M |
| Short-term debt | $335,000 | $307,000 | $280,000 | $252,000 | — | $4.3M | $4.2M | $4.2M | $4.1M | $4.0M | $3.8M | $3.7M |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | — | $9.9M |
| Total current liabilities | $24.8M | $16.1M | $25.2M | $18.8M | $58.8M | $16.7M | $18.6M | $14.3M | $13.8M | $13.2M | $15.6M | $15.4M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $2.9M | $2.9M | $3.0M | $3.1M | $0 | $30.8M | $31.8M | $32.9M | $33.8M | $34.7M | $35.7M | $36.6M |
| Other long-term liabilities | $656.4M | $641.1M | $603.3M | $2.38B | $1.65B | $26.5M | $27.6M | $28.7M | $29.7M | $30.8M | $43.5M | $32.9M |
| Total liabilities | $681.2M | $657.2M | $628.4M | $2.40B | $1.71B | $43.2M | $46.2M | $43.0M | $43.5M | $44.0M | $59.1M | $48.2M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $19,000 | $19,000 | $18,000 | $15,000 | $13,000 | $13,000 | $13,000 | $7,000 | $7,000 | $7,000 | $7,000 | $7,000 |
| Retained earnings (deficit) | −$1.44B | −$1.37B | −$1.15B | −$2.88B | −$2.06B | −$489.5M | −$457.0M | −$426.3M | −$398.7M | −$370.9M | −$340.1M | −$313.8M |
| Accumulated other comprehensive income | −$922,000 | −$706,000 | $41,000 | $12,000 | $14,000 | $23,000 | $22,000 | $68,000 | −$70,000 | −$87,000 | −$77,000 | −$280,000 |
| Total shareholders' equity | −$200.2M | −$150.4M | −$164.3M | −$2.23B | −$1.51B | $66.1M | $96.7M | $73.0M | $98.1M | $123.0M | $150.7M | $174.8M |
| Key figures | ||||||||||||
| Total debt | $2.9M | $2.9M | $3.0M | $3.1M | — | $30.8M | $31.8M | $32.9M | $33.8M | $34.7M | $35.7M | $36.6M |
| Net cash (debt) | $463.3M | $488.6M | $452.2M | $167.4M | — | $29.3M | $60.1M | $30.0M | $52.1M | $72.7M | $101.5M | $123.5M |
| Working capital | $450.3M | $484.7M | $432.9M | $153.6M | $146.2M | $48.1M | $77.9M | $53.0M | $76.5M | $98.6M | $125.2M | $149.1M |
| Tangible book value | −$200.2M | −$150.4M | −$164.3M | −$2.23B | −$1.51B | $66.1M | $96.7M | $73.0M | $98.1M | $123.0M | $150.7M | $174.8M |
| Book value per share | −$3.69 | — | — | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 54.3M | — | — | — | — | — | — | — | — | — | — | — |
| Current ratio | 19.15 | 31.15 | 18.20 | 9.16 | 3.49 | 3.88 | 5.19 | 4.69 | 6.54 | 8.46 | 9.04 | 10.69 |
| Quick ratio | 18.78 | 30.57 | 18.08 | 9.05 | 3.45 | 3.59 | 4.94 | 4.38 | 6.23 | 8.13 | 8.81 | 10.40 |
| Debt / equity | — | — | — | — | — | 0.47 | 0.33 | 0.45 | 0.34 | 0.28 | 0.24 | 0.21 |
| Equity / assets | −41.6% | −29.7% | −35.4% | −1,262.8% | −733.2% | 60.4% | 67.6% | 62.9% | 69.3% | 73.7% | 71.8% | 78.4% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 30, 2026); data from EODHD.
VOR financial position
At the end of fiscal 2025 (December 31, 2025), Vor Biopharma had total assets of $464.1 million (up 224.8% from a year earlier), total liabilities of $628.4 million and shareholders' equity of -$164.3 million. It held $455.2 million in cash and short-term investments against $3.0 million of debt, a net cash position of $452.2 million. Its current ratio was 18.20. In the latest quarter (ended June 30, 2026) total assets were $481.1 million and equity -$200.2 million.
Related: VOR income statement, VOR cash flow statement, VOR key metrics. See the VOR stock overview for the latest quote and news.
VOR balance sheet FAQ
What are Vor Biopharma's total assets?
Vor Biopharma reported total assets of $464.1 million at the end of fiscal 2025 (December 31, 2025), compared with $142.9 million a year earlier.
How much debt does Vor Biopharma have?
Vor Biopharma had $3.0 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Vor Biopharma have?
Vor Biopharma held $455.2 million in cash and short-term investments at the end of fiscal 2025; with $3.0 million of debt that is net cash of $452.2 million.
What is Vor Biopharma's book value?
Vor Biopharma's shareholders' equity (book value) was -$164.3 million at the end of fiscal 2025.
What is Vor Biopharma's current ratio?
Vor Biopharma had current assets of $458.1 million and current liabilities of $25.2 million, a current ratio of 18.20 (it can cover its short-term obligations).